CN-121978344-A - Application of myocardial injury marker RSPO1 in preparation of products for identifying cardiovascular diseases

Abstract

The application relates to application of a myocardial injury marker RSPO1 in preparation of a product for identifying cardiovascular diseases. The application evaluates the expression profile of all ligands of LGR4 under cardiovascular diseases at present and provides application of RSPO1 as a potential drug target, and based on the application, the application further provides application of a myocardial damage marker RSPO1 in preparing products for identifying cardiovascular diseases and application of a reagent for detecting the protein level of RSPO1 in preparing products for diagnosing cardiovascular diseases. The application solves the problems of insufficient suitability and specificity of the existing marker, develops RSPO1 as a diagnosis marker, adopts DY4645-05 ELISA kit for detection, adapts to multiple samples such as serum and the like, can diagnose various cardiovascular diseases, is applicable across species, unifies basic research and clinical diagnosis detection systems, and provides powerful support for diagnosis and treatment of cardiovascular diseases.

Inventors

• CHEN KANG
• ZHUANG LINGFANG
• WANG JIQIU
• DAI RUI

Assignees

• 上海交通大学医学院附属瑞金医院

Dates

Publication Date

20260505

Application Date

20251231

Claims (10)

1. 1. Use of cardiac injury marker RSPO1 in the manufacture of a product for identifying cardiovascular disease.
2. 2. Use of an agent for detecting RSPO1 protein levels or RSPO1 genes in the manufacture of a product for diagnosis of cardiovascular diseases.
3. 3. The use according to claim 2, wherein the product comprises a kit and a chip.
4. 4. The use according to claim 2, wherein the reagent for detecting RSPO1 protein level is an antibody capable of binding specifically to RSPO 1.
5. 5. The use according to claim 2, wherein the cardiovascular disease is selected from one or more of atherosclerosis, ischemic cardiomyopathy, hypertrophic cardiomyopathy, heart failure.
6. 6. Use according to claim 2, wherein the reagent for detecting RSPO1 protein level or RSPO1 gene is directed against a biological sample selected from serum, plasma, whole blood or saliva.
7. 7. A product for diagnosis of cardiovascular disease, characterized in that the product comprises an agent for RSPO1 protein levels or genes for RSPO 1.
8. 8. The product of cardiovascular disease diagnosis according to claim 7, wherein the product comprises a kit and a chip.
9. 9. The product of claim 7, further comprising a reagent for treating a biological sample selected from the group consisting of serum, plasma, whole blood, and saliva.
10. 10. The application of the mutant of the humanized RSPO1 in preparing an ischemic cardiomyopathy model is characterized in that the mutant of the humanized RSPO1 is R219W point mutation of the humanized RSPO 1.

Description

Application of myocardial injury marker RSPO1 in preparation of products for identifying cardiovascular diseases Technical Field The invention relates to the technical field of biological medicine and biomedical detection, in particular to application of a myocardial damage marker RSPO1 in preparation of a product for identifying cardiovascular diseases. Background Heart failure is the final stage of various heart diseases and is a major public health problem that currently jeopardizes human health. Among them, heart failure due to coronary atherosclerotic heart disease (coronary heart disease) accounts for about 50% of all causes, leading to heart failure. Although timely reperfusion therapy can reduce the early mortality and complications of coronary heart disease and myocardial infarction patients, ventricular remodeling and heart failure still occur in a plurality of myocardial infarction patients along with time, which are important reasons for repeated hospitalization and even death after myocardial infarction of coronary heart disease patients, and seriously affect the long-term prognosis of coronary heart disease patients. At present, the pathophysiological processes and specific mechanisms of heart failure caused by myocardial infarction are not yet fully elucidated. The method is beneficial to intervening, delaying and even avoiding the heart failure of the myocardial infarction patients, improving the prognosis of the myocardial infarction patients and having very important practical significance for pushing the basic research of myocardial infarction to clinical transformation and application. Previous studies have shown that coordinating ordered inflammatory responses and recruitment of inflammatory cells, phenotype switching, plays an important role in regulating myocardial infarction injury repair and ventricular remodeling. In this process, macrophages, the most abundant inflammatory cells in heart tissue, are the core component in the myocardial infarction immune microenvironment. On one hand, macrophages participate in myocardial cell reaction after myocardial infarction through high-efficiency phagocytosis and necrosis of myocardial cells, and simultaneously cooperate to regulate and control the reaction of non-myocardial cells after myocardial infarction, so as to participate in regulating the functions of neutrophils, fibroblasts and endothelial cells. Early animal experimental research shows that macrophage specific Lgr4 knockout can significantly inhibit infiltration of pro-inflammatory macrophages and expression of inflammatory cytokines, and increase the number of Ly6 clow-anti-inflammatory macrophages, so that the occurrence and development of ventricular remodeling and heart failure after myocardial infarction are improved, however, potential ligands and upstream regulation and control mechanisms of the potential ligands in cardiovascular diseases are not clear. CN121027535A discloses the use of IGSF1 protein as a marker for cardiac functional recovery. There is provided the use of a protein comprising one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4 as a marker for the preparation of a product for the detection and/or diagnosis of heart failure with improved ejection fraction. A novel serum marker is provided whose expression level predicts with high accuracy heart failure patients with reduced ejection fraction having cardiac function recovery potential, and whose changes are earlier than changes in ejection fraction. CN118443947a discloses an early circulating plasma biomarker Amyloid P Component (APCS) for detecting coronary atherosclerotic heart disease and its application, and also discloses the application of the biomarker in preparing diagnostic kit or diagnostic reagent for distinguishing coronary heart disease patient from normal person. The biomarker is screened by human plasma proteomics technology, has higher sensitivity and specificity as a molecular marker, and is verified by plasma ELISA, so that APCS is possibly involved in the onset of coronary heart disease, and can be used as an early diagnosis biomarker and a new treatment target of coronary heart disease. However, the above prior art lacks key molecules for Lgr 4-metabolic recoding-macrophage phenotype conversion. Therefore, the key molecules (or ligands) for regulating and controlling the Lgr 4-metabolism recoding-macrophage phenotype conversion are searched, so that the method is favorable for accurately regulating and controlling the macrophage phenotype conversion, reducing inflammatory reaction, and also favorable for the research and development of clinical medicines such as neutralizing antibodies and the like and the clinical intervention, and has important value for preventing and treating heart failure after myocardial infarction. Disclosure of Invention In order to better identify cardiovascular diseases, the invention provides application of a myocardia